Technical notes

The effects of atorvastatin therapy on endothelial function in patients with coronary artery disease

Ahmet Yildiz*1, M Akif Cakar2, Murat Baskurt2, Baris Okcun2, Deniz Guzelsoy2 and Ugur Coskun2

Address: 1Department of Cardiology, Gazi Hospital, Izmir, Turkey and 2Department of Cardiology, Institute of Cardiology, Istanbul University, Istanbul, Turkey

Email: Ahmet Yildiz* - drayildiz@yahoo.com; M Akif Cakar - makifcakar@yahoo.com; Murat Baskurt - drmuratbaskurt@yahoo.com; Baris Okcun - drabarıs_2000@yahoo.com; Deniz Guzelsoy - denizguzelsoy@yahoo.com; Ugur Coskun - ucoskun1@yahoo.com

* Corresponding author

Abstract

Background: Statins improve the endothelial function in patients with coronary artery disease (CAD). However, they contribute to the substantial decrease in coronary heart disease by reducing plasma cholesterol levels. They also, reduce oxidative stress, stabilize the atherosclerotic plaque and inhibit inflammatory response. These functions of statins have been briefly described as pleiotropic effects. The aim of our study was to evaluate the effect of atorvastatin therapy on endothelial functions in patients with CAD.

Methods: Forty-nine patients (40 men, 9 women, mean age 59 +/- 11 years) with diagnosed CAD were selected as the study group. The patients were given 10 mg/day atorvastatin for 12 weeks. If the target cholesterol levels has not been achieved 6 weeks after the treatment, then the daily atorvastatin dosage has been increased. The endothelial function was evaluated by flow mediated dilatation (FMD) of the brachial artery.

Results: It has been figured out that 12 weeks later, atorvastatin caused a statistically significant decrease in the plasma levels of LDL-cholesterol and total cholesterol (p < 0.0001). Meanwhile, it was determined that the FMD got statistically significant improved 12 weeks after the atorvastatin therapy (8.1%–4.2%, p < 0.001). However there was no statistically significant change in non-endothelium dependent dilatation (NID).

Conclusion: Endothelium derived vasodilatation (EBD), which was non-invasively detected via brachial artery ultrasonography, had statistically significant improvement within 12 weeks of atorvastatin therapy whereas non-endothelium dependent dilatation (NID) had no change.

Introduction

The endothelium plays a vital role on the process of atherosclerosis; and it functions as a barrier between the blood and wall of the vessel [1,2]. Hypercholesterolemia is highly associated with impaired endothelial function. Endothelial dysfunction (ED) has a predictive value about the future cardiovascular events [3]. ED is reversible during the early stages of atherosclerosis. Some of the systemic markers of inflammation such as C-reactive protein (CRP) may also have predictive value for the future cardi-
vascular events in healthy subjects, in elderly patients and in individuals with high risk. The serum level of CRP is directly correlated with the presence and severity of coronary, cerebral and peripheral arterial atherosclerosis [4]. Beyond their lipid lowering effects, statins may improve endothelial function, reduce CRP and the risk of cardiovascular events. The endothelial function can be non-invasively evaluated by FMD of the brachial artery. The aim of our study was to evaluate the effects of atorvastatin therapy on serum lipid levels and to evaluate the effect of atorvastatin on endothelial function assessed by FMD of brachial artery in patients with diagnosed CAD.

Materials and methods

Study population
Fourty-nine patients (40 men, 9 women, mean age 59 +/- 11 years) with diagnosed CAD were selected as the study group. The inclusion criteria for the study were described as; having coronary artery lesions on coronary angiography or previous myocardial infarction onset of which was older then 6 months, having a LDL-cholesterol level higher then 130 mg/dl and triglyceride level lower then 300 mg/dl and for diabetic population having a fasting glucose level lower then 180 mg/dl and HbA1C level below 8%. Our exclusion criteria were: having a lipid lowering drug therapy for the last two months, undergoing any surgical operation within last 6 months, having an anticoagulant therapy, renal or hepatic failure, uncontrolled systemic hypertension (systolic>160 mmHg, diastolic > 100 mmHg), having a myocardial infarction, unstable angina, stroke, angioplasty and/or coronary artery bypass surgery within the period of last 6 months. Ten of 59 patients were excluded from the study due to the discordance in the treatment.

Study design
All of the patients were evaluated at the beginning of the study and at the 6th and 12th week of the study. Any patient who had not been taking aspirin therapy was given 300 mg aspirin daily and study was started two weeks later.

1) Initial evaluation
At the beginning of the study a detailed medical history was obtained, demographic data including the heights and weights of the patients was collected and a detailed physical examination was performed. For analysing the fasting glucose level, lipid profile, liver functional tests, fibrinogen and CRP, blood samples were taken. For the assessment of the endothelial function before the treatment, brachial arterial ultrasonography which is a non-invasive test was performed. Later on all of the patients were given NCEP step 2 diet. Special attention was paid on not to change any other drug therapy that the patient has already been receiving. Atorvastatin dosage was ordered as 10 mg per day for patients whose initial LDL cholesterol levels were below 180 mg/dl and 20 mg per day for patients whose initial LDL levels were above 180 mg/dl.

2) 6th week evaluation
The patients whose hepatic functional tests were two times higher then their initial levels were excluded from the study. The aim of the therapy was to achieve either a 30% decrease in the level of LDL cholesterol or a level under 125 mg/dl. When the expected level of LDL cholesterol was not reached then the atorvastatin dosage was increased to 20 mg per day for patients receiving 10 mg per day and to 30 mg per day for patients receiving 20 mg per day.

3) 12th week evaluation
Blood samples were taken for the re-measurement of fasting glucose level, lipid profile, liver functional tests, fibrinogen and CRP and brachial arterial ultrasonography was repeated.

The vasomotor function of brachial artery can be evaluated by brachial arterial ultrasonography and this method is well correlated with coronary artery vasomotor function [5]. So, we preferred to perform brachial arterial ultrasonography for assessing the endothelial function. The protocol for the flow mediated dilation is performed according to guidelines, by Corretti. M.C. et al. [6] The medications such as nitrates, calcium antagonists, angiotensin converting enzyme inhibitors and beta blockers have been discontinued one day before the examination. The patients were wanted to lay down in supine position. Two-dimensional images of 10–20 mm slices of the right brachial artery were obtained via 8.5 MHz linear transducer. Later on, the largest diameter of the artery was measured during systole via M-mode imaging. The measurements were repeated three times and the arithmetic medians were calculated. After the measurement, 250 mmHg pressure was applied to the same upper extremity with a cuff for 5 minutes. After loosening the cuff, the ultrasonographic views were recorded for 3 minutes and the largest diameter of the vessel in systole was measured (Endothelium dependent vasodilatation-EDV) (Reactive hyperemia). After the diameter of the vessels returned to their resting state (10 minutes later), the patient was given 2.5 mg sublingual nitroglycerin spray and then the images were recorded for 5 minutes and the largest diameter of the vessel during systole was reached (Vasodilatation independent from endothelium-NID).

Rates of EDV and NID were obtained in percentage according to the ratio between the arterial diameters measured at rest and arterial diameters measured after
reactive hyperemia and application of nitroglycerin. The calculation was made according to the formula below.

% change = (D2-D1)/D1 × 100%

D1 was the initial diameter while D2 was the diameter measured after atorvastatin therapy.

**Plasma lipid and C-Reactive Protein levels**

Lipid profiles and hepatic functional tests of the patients were analyzed at the beginning, at the sixth week and at third month of the therapy. The total cholesterol levels were measured by Technicon Opera autoanalyser by using trading kit (biotrol) after it dissolved. CRP was checked by using high sensitive Dade Behring kit on Dade Behring Nephelometer 100 device. Dilution was applied to high levels. CRP levels under 0.34 mg/L were accepted as normal while the levels higher were accepted as pathological.

**Statistical analysis**

In our study, quantitative factors were indicated as arithmetic means +/- standard deviation and qualitative factors were indicated as percentage. Matched t test was used for the comparison of the brachial arterial diameters. The total cholesterol level was evaluated via Pearson correlation analysis according to the % change between LDL and EBD. The correlation was considered as statistically significant for whom the coefficient of correlation was higher then 0.05. The SPSS 11.0 package statistics program was used for statistical work.

**Results**

The demographical characteristics, coronary angiographic findings and the medications have been summarised in Table 1. Initially, 10 mg atorvastatin was given to 41 patients (83.6%) and 20 mg to 8 patients (16.3%) and the dosages were increased substantially according to the control levels at the sixth week of the therapy. No significant increase was seen in the liver functional tests in any control evaluation.

**Effects of atorvastatin on serum lipid and CRP levels**

It has been seen that the total cholesterol and LDL cholesterol levels got significantly decreased at the third month of the atorvastatin therapy. The total decrease was 32.4% for total cholesterol level and was 42.3% for LDL cholesterol level. The triglyceride levels and HDL cholesterol levels were not changed significantly. With atorvastatin treatment, the rate of decrement in fibrinogen levels was 8.2 % (p < 0.05) while it was 31.6 % (p < 0.001) in CRP levels.

**The results of brachial arterial ultrasonography**

The brachial artery diameter was 3.81 +/- 0.43 mm at resting state before treatment. At the third month of the ator-
inhibition of constructor substance formation by aspirin via the cyclooxygenase pathway [11].

Hypercholesterolemia is the most important risk factor in the development of coronary atherosclerosis [12]. The deterioration of endothelium dependent on vasodilatation has been found to be related with hypercholesterolemia [12-15].

The oxidized LDL, which gets increased in hypercholesterolemia and atherosclerosis cause impairment of endothelial vasodilatation by decreasing NO synthase activity [16]. The deterioration of EBD takes place before the formation of atherosclerotic lesions [12-14]. Hypercholesterolemia causes deterioration of EBD and then myocardial perfusion decreases [12-17]. Statins enhance the endothelial vasodilator and fibrinolytic capacity by lowering the oxidized LDL.

The use of statins in patients with CAD and hyperlipidemia results in improvement of both endothelial functions of coronary arteries and myocardial perfusion [18-21]. The main causative substrate for this improvement is endothelium derived relaxing factor (EDRF = NO). Within 24 weeks of fluvastatin therapy, an increase in the forearm blood flow through plethysmography has been detected in hyperlipidemic patients with an inverse ratio of LDL levels [22]. The same beneficial effect has been also reported with 4 weeks of simvastatin therapy [23]. In RECIFE study, improvement in endothelial functions with pravastatin use (40 mg/d) has been shown in such a short time as 6 weeks [24].

In a study, Anderson et al. randomized 49 patients into three groups with average serum cholesterol levels of 209 +/- 33 mg/dl [25]. At the end of the first year, a significant improvement in the coronary artery dilatation by Ach has been observed. Consequently, the authors indicated that an improvement in endothelial functions could be obtained in patients with CAD and unfavorable cardiac events could be reduced with the combination of cholesterol lowering therapy with antioxidant therapy.

In our study we hold a group that contained patients with high risk (diagnosed CAD, 30% incidence of diabetes mellitus) and we examined the effect of atorvastatin on endothelial functions, by evaluating the EDV and NID on brachial artery before and after 12 weeks of atorvastatin therapy. At the end of 12 weeks, LDL cholesterol levels showed a decrease of 42.3% and endothelium dependent vasodilatation showed a 92% increase. We found no significant change in NID with atorvastatin therapy. Our results were similar to the other statin studies (RECIFE etc.) [24]. However, the method we used is a very simple method highlighting the general status of the circulatory system. Because it depends on ultrasonography, the examination requires experience.

As a result, in the adults who have normal vascular function, a marked improvement in endothelial functions with 80 mg/day atorvastatin therapy was observed within 24 hours and this improvement came out before cholesterol lowering activity. However, it has been seen that vascular functions deteriorated acutely irrespective of cholesterol levels after cessation of atorvastatin therapy [26].

**Conclusion**

Statins have cholesterol lowering effects and recover endothelial dysfunction which contributes to atherosclerosis in patients with hypercholesterolemic ischemic cardiac disease. The improvement in endothelial functions may play a significant role in reducing the risk of future coronary events. It is important to use statins for a long time, because of rapid deterioration of endothelial functions occurs shortly after cessation of statin therapy.

**References**

1. Rossouw JE, Lewis B, Rifkind BM. The value of lowering cholesterol after myocardial infarction. *N Engl J Med* 323(16):1129-9. 1990 Oct 18
2. Vita JA, Keaney JF Jr: Hormone replacement therapy and endothelial function: the exception that proves the rule? *Arterioscler Thromb Vasc Biol* 21:1867-1869. 2001
3. West of Scotland Coronary Prevention study group: Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention study (WOSCOPS). *Circulation* 97(15):1440-1445. 1998 Apr 21
4. Smith GD, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentration and mortality. *The Whitehall Study*. *J Am Med Assoc* 267(1):70-6. 1992 Jan 1
5. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delgrange D, Lieberman EH, Ganz P, Creager MA, Yeung AC, Selwyn AP. Close relation of endothelial function in the human coronary and peripheral circulations. *J Am Coll Cardiol* 26:1235-1241. 1995 Nov 1
6. Cocorazzi MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R, International Brachial Artery Reactivity Task Force: Guidelines for the ultrasound assessment of endothelium-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. *J Am Coll Cardiol* 39(2):257-65. 2002 Jan 16
7. Lieberman EH, Gerhard MD, Uehata A, Selwyn AP, Ganz P, Yeung AC, Creager MA. Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. *Am J Cardiol* 78(11):1210-4. 1996 Dec 1
8. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OL, Sullivan ID, Lloyd JK, Deanfield JE: Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. *Lancet* 340:1111-1115.
9. Eleuteri E: Comparative study of the effect of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study). * Ital Heart J Suppl 2000; 1(6):830-831.
10. Mancini GB, Henry GC, Masaya C, O'Neill BJ, Pagallo AR, Carese RG, Wargovich TJ, Mudra H, Lüscher TF, Klabiner MI, Haber HE, Uprichard AC, Pepine CJ, Pirt B: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. *The TREND (Trial on Reversing ENDothelial Dysfunction) Study. Circulation* 94(3):258-265. 1996 Aug 1
11. Husain S, Andrews NP, Mulcahy D, Panza JA, Quyyumi AA: Aspirin improves endothelial dysfunction in atherosclerosis. *Circulation* 97(8):716-720.

12. Brown BG, Zhao XQ, Sacco DE, Albers JJ: Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease. *Circulation* 1993, 87(6):1781-1791.

13. Lucher TF, Richard V, Tschudi M, Yang ZH, Boulanger C: Endothelial control of vascular tone in large and small coronary arteries. *J Am Coll Cardiol* 15(1):519-27. 1990 Mar 1

14. Chowienczyk Pj, Watts GF, Cockcroft JR, Brett SE, Ritter JM: Sex differences in endothelial function in normal and hypercholesterolaemic subjects. *Lancet* 344:305-306. 1994 Jul 30

15. Susekov AV, Rozhkova TA, Tripoten' MI, Pogorelova OA, Kulev BD, Balakhonova TV, Zubareva Ml, Masenko VP, Rogozova AN, Kukhar-chuk VV: Randomized FARVATER study. Effect of atorvastatin on endothelial function, distensibility and stiffness of vascular wall. *Kardiologiia* 2007, 47(2):25-30.

16. Martinez-González J, Badimon L: Influence of statin use on endothelial function: from bench to clinics. *Curr Pharm Des* 2007, 13(17):1771-86.

17. Zeiher AM, Drexler H, Wollschläger H, Just H: Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. *Circulation* 1991, 83(2):391-401.

18. Zeiher AM, Drexler H, Saurbier B, Just H: Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hypercholesterolemia, and hypertension. *J Clin Invest* 1993, 92(2):652-662.

19. van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV: Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. *REGRESS Study Group* *Circulation* 94(7):1503-1505. 1996 Oct 1

20. Tzivoni D, Klein J: Improvement of myocardial ischemia by lipid lowering drugs. *Eur Heart J* 1998, 19(2):230-234.

21. Bellosta S, Bernini F, Ferri N, Quarto P, Canavesi M, Arnaboldi L, Fumagalli R, Pialetti R, Corsini A: Direct vascular effects of HMG-CoA reductase inhibitors. *Atherosclerosis* 1998, 137(Suppl):S101-9.

22. Eichstädt HW, Eskotter H, Hoffmann I, Amthauer HW, Weidinger G: Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. *Am J Cardiol* 76(2):122A-125A. 1995 Jul 13

23. O’Driscoll G, Green D, Taylor RR: Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. *Circulation* 95(3):1126-1131. 1997 Mar 4

24. Dupuis J, Tardif JC, Cemacek P, Theroux P: Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes – The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. *Circulation* 1999, 99:3227-3233.

25. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. *N Engl J Med* 332(8):488-93. 1995 Feb 23

26. Laufs U, Wassmann S, Hilgers S, Ribauo N, Böhm M, Nickeng G: Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men. *Am J Cardio* 88(11):1306-7. 2001 Dec 1